Cargando…
Prescription of Anti-Spike Monoclonal Antibodies in COVID-19 Patients with Resistant SARS-CoV-2 Variants in Italy
Anti-Spike monoclonal antibodies have been considered a promising approach to COVID-19 therapy. Unfortunately, the advent of resistant lineages jeopardized their effectiveness and prompted limitations in their clinical use. Change in the dominant variant can be fast to such an extent that, in the ab...
Autores principales: | Focosi, Daniele, Tuccori, Marco |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9331784/ https://www.ncbi.nlm.nih.gov/pubmed/35894046 http://dx.doi.org/10.3390/pathogens11080823 |
Ejemplares similares
-
Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline
por: Tuccori, Marco, et al.
Publicado: (2020) -
Monoclonal antibody therapies against SARS-CoV-2
por: Focosi, Daniele, et al.
Publicado: (2022) -
SARS-CoV-2 Variants: A Synopsis of In Vitro Efficacy Data of Convalescent Plasma, Currently Marketed Vaccines, and Monoclonal Antibodies
por: Focosi, Daniele, et al.
Publicado: (2021) -
The Road towards Polyclonal Anti-SARS-CoV-2 Immunoglobulins (Hyperimmune Serum) for Passive Immunization in COVID-19
por: Focosi, Daniele, et al.
Publicado: (2021) -
The Omicron variant of concern: Diversification and convergent evolution in spike protein, and escape from anti-Spike monoclonal antibodies
por: Focosi, Daniele, et al.
Publicado: (2022)